These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 37099940)
1. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8 Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940 [TBL] [Abstract][Full Text] [Related]
2. PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients. Al-Mterin MA; Murshed K; Elkord E Cancer Immunol Immunother; 2023 Jun; 72(6):1933-1939. PubMed ID: 36436018 [TBL] [Abstract][Full Text] [Related]
3. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406 [TBL] [Abstract][Full Text] [Related]
4. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950 [TBL] [Abstract][Full Text] [Related]
5. Expression of immune checkpoints in T cells of esophageal cancer patients. Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071 [TBL] [Abstract][Full Text] [Related]
6. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma. Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520 [TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer. Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675 [TBL] [Abstract][Full Text] [Related]
8. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981 [TBL] [Abstract][Full Text] [Related]
9. TOX-expressing terminally exhausted tumor-infiltrating CD8 Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194 [TBL] [Abstract][Full Text] [Related]
10. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E Front Immunol; 2019; 10():2936. PubMed ID: 31921188 [TBL] [Abstract][Full Text] [Related]
13. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919 [TBL] [Abstract][Full Text] [Related]
14. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222 [TBL] [Abstract][Full Text] [Related]
15. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514 [TBL] [Abstract][Full Text] [Related]
16. Presence of Tim3 Klapholz M; Drage MG; Srivastava A; Anderson AC J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692 [TBL] [Abstract][Full Text] [Related]
17. The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment. Neupane P; Mimura K; Nakajima S; Okayama H; Ito M; Thar Min AK; Saito K; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Kono K Anticancer Res; 2021 Oct; 41(10):4895-4905. PubMed ID: 34593437 [TBL] [Abstract][Full Text] [Related]
18. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831 [TBL] [Abstract][Full Text] [Related]
19. Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients. Jiang K; Liu S; Chen Y; Xu Z; Xu Z; Qian B; Ding Q; Cui H; Sui Y; Cao D; Xu W; Shen M Thorac Cancer; 2023 Sep; 14(27):2745-2753. PubMed ID: 37536668 [TBL] [Abstract][Full Text] [Related]